Albany Molecular Research (AMRI) says ‘streamlining’ plan will focus on its drug licensing unit not its contract API research, development and manufacturing services division.
Rousselot says its acquisition of Eastman Kodak’s Gel Corporation will boost its gelatine production capacity and help it meet soaring drug industry demand.
Further analysis is needed to assess the risk posed by low level pharmaceutical contamination of water supplies says the winner of Recipharm’s 2011 environmental award.
ACRO says latest draft rules on trials in India – which would see ethics committees take sole responsibility for determining SAE cause and compensation - are a backwards step that would make high quality research impossible.
The US Food and Drug Administration (FDA) will soon start asking drugmakers to play a greater role in guideline development. Before that process begins in-Pharmatechnologist.com takes a look at the documents published by the agency in 2011.
GSK CEO Andrew Witty has been knighted in the Queen's New Year Honours list in recognition of his services to the UK economy and pharmaceutical industry.
Manufacturing operations at Shasun Pharma’s plant in Cuddalore, Tamil Nadu are still suspended days after Southern India was battered by a cyclonic storm.
in-PharmaTechnologist presents its first weekly round-up of the new appointments in the industry of 2012, including news from Teva, Forma Therapeutics and Celgene.
The ENCePP (European network of centres for pharmacoepidemiology and pharmacovigilance) is seeking to facilitate better interaction with biopharm companies on post-authorisation studies.
US CRO PPS Clinical Research has admitted that an employee falsified patient record during a trial of Boehringer Ingelheim’s failed ‘female Viagra,’ Flibanserin.
Ben Venue Laboratories will not restart manufacturing at its plant in Bedford, Ohio until later this quarter – at the earliest - after extending the voluntary suspension it implemented in November.
Contract testing services supplier LabCorp has secured a credit facility with the Bank of America, citing capital expenditures and acquisitions among the potential uses of the funds.
Outsourcing-Pharma presents its weekly round-up of the latest appointments within the pharmaceutical industry, including news from Patheon, Cetero and Roche.
It’s been a busy year for API (active pharmaceutical ingredient) manufacturers with new facilities, cost pressures and regulatory developments all hitting the headlines.And it seems recent developments in HPAPIs (high potency APIs) have caused a stir...
Europe’s Innovative Medicines Initiative (IMI) has adopted the Clinical Data Interchange Standards Consortium’s (CDISC) standards for all future projects in a move announced this week.
Quintiles says its alliance with Intarcia Therapeutics – developer of an injection-free diabetes drug – uses a financing model that could replace “old-fashioned” outsourcing business relationships.
China will keep its position as a leading API and intermediates supplier thanks to recovering global demand and the growth of the generic sector say market analysts.
